Posted: August 2018
Leena Gandhi, MD, PhD, has become head of oncology for Eli Lilly and Company, where she will direct research of the company’s immuno-oncology products. Previously, she was director of thoracic medical oncology at New York University (NYU) Langone Medical Center LLC. Prior to joining NYU Langone and the Perlmutter Cancer Center, Dr. Gandhi served at the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, where she was a medical oncologist and clinical investigator in the Lowe Center for Thoracic Oncology and in the Early Drug Development Center. Dr. Gandhi played a leading role in numerous clinical trials, including the pivotal KEYNOTE-189, which she presented at the American Association for Cancer Research meeting in April 2018.
